The Company's participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum accelerates
CAESAREA, Israel , March 26, 2026 /PRNewswire/ -- IceCure Medical Ltd . (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology...
At a median follow-up of four years, 89.4% recurrence-free rate in patients with tumors ≤3 cm and no prior kidney cancer; 83.9% recurrence-free rate for general study population
Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companies
Record 4 th quarter and full year sales of $1.3 million and $3.4 million, respectively
IceCure is engaged with leading medical institutions throughout the U.S. looking to participate in the post-market study with the FDA-cleared ProSense®
CAESAREA, Israel , March 10, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology...
IceCure's ICE3 study and the FDA Advisory Panel's favorable vote on ProSense® cryoablation's benefit-risk profile for low-risk breast cancer played a key role in the ASBrS 2026 Resource Guide update
Treatment with ProSense® resulted in 92.9% volume reduction of fibroadenoma one-year post-cryoablation
Previously released interim data from 111 patients demonstrated ProSense® is safe and effective in destruction of kidney tumors with 88.7% recurrence-free rate